Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Arovella Therapeutics Limited Business Overview & Revenue Model
Arovella Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 136.00K | 136.00K | 17.00K | 405.90K | 295.81K | 257.35K |
| Gross Profit | 136.00K | 136.00K | -25.98K | -3.00M | 88.75K | 34.60K |
| EBITDA | -18.92M | -11.10M | -10.63M | -10.37M | -7.87M | -4.99M |
| Net Income | -7.51M | -7.51M | -8.75M | -10.18M | -8.62M | -5.05M |
Balance Sheet | ||||||
| Total Assets | 21.60M | 21.60M | 13.28M | 5.47M | 9.21M | 10.69M |
| Cash, Cash Equivalents and Short-Term Investments | 20.88M | 20.88M | 12.71M | 5.18M | 6.07M | 6.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 144.80K | 79.23K |
| Total Liabilities | 1.52M | 1.52M | 2.06M | 1.69M | 1.60M | 1.71M |
| Stockholders Equity | 20.08M | 20.08M | 11.23M | 3.78M | 7.62M | 8.98M |
Cash Flow | ||||||
| Free Cash Flow | -7.34M | -7.34M | -7.04M | -6.40M | -6.83M | -4.06M |
| Operating Cash Flow | -6.93M | -6.93M | -6.91M | -6.40M | -6.27M | -3.54M |
| Investing Cash Flow | -432.11K | -432.11K | -179.34K | 95.42K | -566.00K | -514.55K |
| Financing Cash Flow | 15.52M | 15.52M | 14.61M | 5.41M | 6.19M | 9.80M |
Arovella Therapeutics Limited Technical Analysis
Arovella Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$73.62M | 11.04 | 27.24% | 2.81% | 0.65% | -9.90% | |
52 Neutral | AU$166.28M | -6.38 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$114.11M | -13.97 | -47.98% | ― | 700.00% | 26.88% | |
43 Neutral | AU$66.70M | -6.47 | -27.39% | ― | ― | 26.64% | |
41 Neutral | AU$87.00M | -5.26 | -42.68% | ― | ― | 63.46% | |
41 Neutral | AU$80.94M | -8.11 | -71.87% | ― | 7.65% | -19.13% |
Arovella Therapeutics Limited Corporate Events
Arovella Therapeutics has received U.S. Food and Drug Administration acceptance of its investigational new drug application for ALA-101, clearing the way for first-in-human Phase 1 trials in patients with relapsed or refractory CD19-positive non-Hodgkin’s lymphoma and leukaemia. The FDA decision validates ALA-101’s preclinical, manufacturing and development plans, de-risks the program, and enables Arovella to run its initial trial more efficiently in Australia under the CTN scheme while also opening sites in the U.S., creating a regulatory framework that can be leveraged for follow-on CAR-iNKT candidates such as ALA-105 and other solid tumour programs, thereby strengthening the company’s position in next-generation allogeneic cell therapies and potentially accelerating patient access to off-the-shelf treatments.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics reported progress in the second quarter of FY26, highlighted by the filing of an Investigational New Drug application with the U.S. FDA for its lead allogeneic CAR-iNKT candidate ALA-101, selection of CRO SAPRO to run a first-in-human phase 1 trial in CD19-positive lymphoma and leukaemia across Australia and New Zealand, and confirmation of potent activity for its CLDN18.2-targeting CAR within the ALA-105 solid tumour program. The company ended the quarter with $19.4 million in cash, which it expects will fund completion of ALA-101 phase 1 enrolment and advancement of its solid tumour and armouring programs, while the in-licensing of additional CAR and iNKT-related technologies from Baylor College of Medicine and the board appointment of experienced drug developer Dr Andrew Nash are intended to strengthen its technology base, clinical transition and strategic positioning as it moves toward becoming a clinical-stage cell therapy player in 2026.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has appointed Lachie Mallia as Company Secretary and Chief Financial Officer, effective 22 January 2026, replacing fellow Bio101 Financial Advisory director Tim Luscombe, who previously held the roles. Mallia, a director at Bio101 with extensive experience providing outsourced CFO, company secretarial and advisory services to healthcare companies, will oversee ASX communications on listing rule matters, bolstering Arovella’s governance and financial management as it advances its oncology cell therapy pipeline.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has announced that 936,303 ordinary shares, issued on 4 August 2025 as non-cash consideration for investor relations services, will be released from voluntary escrow on 31 January 2026. The move modestly increases the company’s freely tradable share float, potentially enhancing liquidity in its stock while reflecting the use of equity-based payments to support its investor engagement activities.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its lead allogeneic CAR-iNKT cell therapy candidate, ALA-101, targeting CD19-positive non-Hodgkin’s lymphoma and leukaemias. Clearance of the application would enable the company to launch a first-in-human Phase 1 trial in relapsed or refractory CD19-positive blood cancers, with trial sites planned in both Australia and the United States under a more efficient regulatory pathway, marking Arovella’s transition toward becoming a clinical-stage biotech and potentially strengthening its position in the competitive cell therapy market.
Arovella Therapeutics Limited has issued 371,187 ordinary shares without disclosure under the Corporations Act, complying with relevant legal provisions. This move is part of the company’s strategic efforts to strengthen its financial position and support its ongoing development of innovative cancer therapies, potentially enhancing its market presence and stakeholder value.
Arovella Therapeutics Limited has announced the quotation of 371,187 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is likely to enhance the company’s market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder interests positively.
Arovella Therapeutics Limited has announced a change in the director’s interest, with Elizabeth Stoner exercising options to acquire additional ordinary shares. This adjustment reflects a strategic move within the company’s leadership, potentially impacting its market positioning and signaling confidence in the company’s future prospects.
Arovella Therapeutics Limited has issued 1,157,647 ordinary shares without disclosure under specific sections of the Corporations Act, complying with all necessary legal provisions. This issuance supports the company’s ongoing efforts to enhance its position in the biotechnology sector, particularly in developing innovative cancer therapies. The move reflects Arovella’s strategic focus on expanding its therapeutic offerings and strengthening its market presence.
Arovella Therapeutics Limited announced the cessation of 1,242,353 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategy and future growth prospects.
Arovella Therapeutics Limited has announced the quotation of 1,157,647 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move follows the exercise of options or conversion of other convertible securities, potentially enhancing the company’s financial standing and market presence.
Arovella Therapeutics Ltd has announced an investor presentation update, which will be shared during non-deal investor meetings in Sydney, Melbourne, Hong Kong, and Singapore. This presentation aims to inform stakeholders about the company’s progress and strategic direction, potentially impacting its market positioning and investor relations.
Arovella Therapeutics Limited announced a change in the director’s interest, with Debora Barton exercising options to acquire 1,013,333 ordinary shares while disposing of 1,386,667 unlisted options. This transaction, executed via a cashless exercise facility, reflects an adjustment in the director’s securities holdings, potentially impacting the company’s governance and shareholder dynamics.
Arovella Therapeutics Limited has issued 1,013,333 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, complying with all relevant provisions. This move reflects the company’s strategic efforts to strengthen its financial position and support its ongoing development of innovative cancer therapies, potentially enhancing its market presence and stakeholder value.
Arovella Therapeutics Limited announced the cessation of 1,386,667 securities due to the expiry of options or other convertible securities without exercise or conversion as of November 12, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.
Arovella Therapeutics Limited announced the quotation of 1,013,333 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to strengthen its financial position and support its ongoing development projects, potentially enhancing its market presence and providing value to its stakeholders.
Arovella Therapeutics Limited has announced the appointment of Andrew Nash as a director, effective from November 12, 2025. The initial director’s interest notice reveals that Andrew Nash currently holds no relevant interests in securities or contracts related to the company. This announcement is a procedural update required under listing rules, and it provides transparency to stakeholders about the director’s financial interests, ensuring compliance with corporate governance standards.
Arovella Therapeutics Ltd has exercised its exclusive option with Baylor College of Medicine to negotiate a definitive license agreement for chimeric antigen receptor (CAR) and iNKT cell platform intellectual property. This move positions Arovella to enhance its CAR-iNKT cell products, targeting neuroblastoma and liver cancer, with promising early-stage clinical trial results, potentially impacting its industry positioning and stakeholder interests.